RBC balanced immuno-inflammatory signatures identify advanced breast cancer patients on CDK4/6 inhibitors at increased risk of progression and death

IF 4.6 2区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

iScience Pub Date : 2025-05-09 DOI:10.1016/j.isci.2025.112620

Jiayi Ma , Yaohui Wang , Ziping Wu , Liheng Zhou , Yanping Lin , Shuguang Xu , Jie Zhang , Jingsong Lu , Wenjin Yin

{"title":"RBC balanced immuno-inflammatory signatures identify advanced breast cancer patients on CDK4/6 inhibitors at increased risk of progression and death","authors":"Jiayi Ma , Yaohui Wang , Ziping Wu , Liheng Zhou , Yanping Lin , Shuguang Xu , Jie Zhang , Jingsong Lu , Wenjin Yin","doi":"10.1016/j.isci.2025.112620","DOIUrl":null,"url":null,"abstract":"<div><div>The association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) patients receiving cyclin-dependent kinase 4/6 inhibitor (CDKI). Herein, RBC balanced immuno-inflammatory (RBC-IMM) score was developed and capable of predicting progression-free survival (PFS) events (<em>p</em> < 0.001), death (<em>p</em> < 0.001) and grade 3/4 leukopenia (<em>p</em> = 0.010). RBC-IMM score also predicted PFS more accurately than classical-IMM score (AUC = 0.766 and 0.596 respectively, <em>p</em> = 0.005). Besides, clinico+RBC_index exhibited superior performance to clinico_index for 18-month PFS through machine learning (training set: AUC = 0.830 and 0.764 respectively; testing set: AUC = 0.894 and 0.715 respectively). Additionally, liquid chromatography-tandem mass spectrometry identified phosphatidylcholine notably involved in RBC-CDKI interaction, contributing to the construction of clinico+PtdCho_index with better PFS prediction than clinico_index (AUC = 0.854 and 0.733 respectively). These findings indicate that RBC-IMM related parameters have the advantage of identifying benefit and safety in CDKI-treated ABC patients over classical indicators.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112620"},"PeriodicalIF":4.6000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589004225008818","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

The association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) patients receiving cyclin-dependent kinase 4/6 inhibitor (CDKI). Herein, RBC balanced immuno-inflammatory (RBC-IMM) score was developed and capable of predicting progression-free survival (PFS) events (p < 0.001), death (p < 0.001) and grade 3/4 leukopenia (p = 0.010). RBC-IMM score also predicted PFS more accurately than classical-IMM score (AUC = 0.766 and 0.596 respectively, p = 0.005). Besides, clinico+RBC_index exhibited superior performance to clinico_index for 18-month PFS through machine learning (training set: AUC = 0.830 and 0.764 respectively; testing set: AUC = 0.894 and 0.715 respectively). Additionally, liquid chromatography-tandem mass spectrometry identified phosphatidylcholine notably involved in RBC-CDKI interaction, contributing to the construction of clinico+PtdCho_index with better PFS prediction than clinico_index (AUC = 0.854 and 0.733 respectively). These findings indicate that RBC-IMM related parameters have the advantage of identifying benefit and safety in CDKI-treated ABC patients over classical indicators.

查看原文本刊更多论文

红细胞平衡免疫炎症特征识别CDK4/6抑制剂进展和死亡风险增加的晚期乳腺癌患者

对于接受细胞周期蛋白依赖性激酶4/6抑制剂（CDKI）治疗的晚期乳腺癌（ABC）患者，免疫炎症参数（尤其是RBC平衡特征）与生存结局和不良事件的关联仍需进一步研究。在此，我们开发了RBC平衡免疫炎症（RBC- imm）评分，并能够预测无进展生存（PFS）事件(p <；0.001)，死亡(p <；0.001)和3/4级白细胞减少（p = 0.010）。RBC-IMM评分比classic - imm评分更准确地预测PFS （AUC分别为0.766和0.596,p = 0.005）。此外，clinico+RBC_index通过机器学习对18个月PFS表现优于clinico_index(训练集：AUC分别= 0.830和0.764；测试集：AUC分别= 0.894和0.715)。此外，液相色谱-串联质谱分析发现磷脂酰胆碱参与红细胞- cdki相互作用，有助于构建clinico+PtdCho_index，其PFS预测优于clinico_index （AUC分别为0.854和0.733）。这些发现表明，与经典指标相比，RBC-IMM相关参数在cdki治疗的ABC患者中具有识别益处和安全性的优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

iScience Multidisciplinary-Multidisciplinary

CiteScore

7.20

自引率

1.70%

发文量

1972

审稿时长

6 weeks

期刊介绍： Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results. We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.